Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07533006) titled 'A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)' on April 9.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Eli Lilly and Company
Condition:
Alopecia Areata
Intervention:
Drug: LY4005130
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: April 14, 2026
Target Sample Size: 60
Countries of Recruitment:
United States
Canada
China
Netherlands
Poland
South Korea
United Kingdom
Canada
China
Netherlands...